HealthyPEPNCT02962375
Effect of Orange Pomace Fiber on Glycemic Response
A study testing Active in people with Healthy, run by Clinical Nutrition Research Center, Illinois Institute of Technology at 1 site in United States.
Trial summary
Primary object is to determine if 100% orange juice with enzyme-treated orange pomace fiber compared to a 100% orange juice will reduce 2 hr glycemic response as measured by glucose area under the curve. Read more about this study
- Who is it for?
- Ages 20 to 45 yearsHealthy volunteers can take part
- Conditions the study is for
- Healthy
- What is being tested?
- Active
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 12 participants
- Where
- 1 siteUnited States
- Study dates
- 22 Nov 2016to 18 Sep 2017
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 45 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Subject is a male or female, 20-45 years of age, inclusive.
- Subject has a BMI of 20.0-24.9 kg/m2, inclusive and weight ≥ 110 lb. at screening visit.
- Subject is willing to maintain his/her usual physical activity pattern throughout the study period.
- Subject is willing to follow study instructions including compliance with consumption of study beverage, and study visit schedule.
- Subject is judged to be in good health on the basis of the medical history.
- Subject is willing to abstain from alcohol consumption and avoid vigorous physical activity for 24 h prior to and during study visits. Vigorous physical activity is defined as an activity requiring a large amount of effort, causing rapid breathing and a substantial increase in heart rate (e.g., running, fast cycling, and fast swimming).
- Subject understands the study procedures and signs forms documenting informed consent to participate in the study and authorization for release of relevant protected health information to the study Investigator/s and is willing to complete study procedures.
Who cannot join
- Subject has fasting glucose ≥100 mg/dL.
- Subject has uncontrolled hypertension (systolic blood pressure ≥160 mm Hg or diastolic blood pressure ≥100 mm Hg) at screening visit.
- Subject has had major trauma or a surgical event within 2 months of the study.
- Subject has had a weight change ≥4.5 kg within 2 months of visit.
- Subject has a history or presence of clinically important endocrine, cardiovascular (including, but not limited to, atherosclerotic disease, history of myocardial infarction, peripheral arterial disease, stroke), pulmonary, biliary, or gastrointestinal disorders that, in the opinion of the Investigator, could interfere with the interpretation of the study results.
- Subject has a history or presence of cancer in the prior 2 years, except for non-melanoma skin cancer.
Show all 14Show fewer
- Subject has a history of extreme dietary habits, as judged by the Investigator (e.g., Atkins diet, etc.).
- Subject is a vegan or a vegetarian.
- Subject has a history of an eating disorder (e.g., anorexia nervosa, bulimia nervosa, or binge eating) diagnosed by a health professional.
- Subject has a known intolerance or sensitivity to any ingredients in the study products.
- Subject has used medications known to influence carbohydrate metabolism, including, but not limited to adrenergic blockers, diuretics, hypoglycemic medications, and systemic corticosteroids 2 weeks prior to visit 1 and throughout the study.
- Subject is a female, who is pregnant, planning to be pregnant during the study period or lactating.
- Subject is a current smoker. Past smoker abstinence for less than 2 years.
- Subject has participated in any clinical trial within 30d prior to enrollment.
Trial locations and contacts
1 site in 1 country.
United States1 site
Clinical Nutrition Research Center
Chicago, Illinois, 60616
About this study
Official title: Pilot Study to Assess the Effect of Orange Pomace Fiber on Glycemic Response in Healthy Adults
Primary object is to determine if 100% orange juice with enzyme-treated orange pomace fiber compared to a 100% orange juice will reduce 2 hr glycemic response as measured by glucose area under the curve.
Secondary object is to assess if 100% orange juice with enzyme-treated orange pomace fiber compared to a 100% orange juice will reduce 2 hr insulin iAUC response.
Read the detailed description
The study is single-center, randomized, 2-arm, and crossover design. Twelve healthy men and women aged 20-45 will be recruited for the study. Interested subjects will be asked to come to the Clinical Nutrition Research Center (CNRC) on the IIT Campus, Chicago, IL, where the study will take place for a screening visit to determine if they are eligible to participate in the study. The screening visit will take 2-2.5 hours. Prospective subjects must read, sign and date a written Institutional Review Board (IRB) approved Informed Consent Form prior to performing any study procedure.
At the on-site screening visit, subject will be asked to arrive after overnight fasting for 10-12 hours and be well-hydrated. Subject will be instructed to aim for a water intake of at least 8-10 cups for the 24 hours before the screening visit. Determine eligibility to participate includes having subjects to complete a series of questionnaires related to their health, medication use, dietary habits, and physical activity history. Anthropocentric (height, weight and waist circumference), ear temperature, and vital signs (blood pressure and heart rate) will be measured. Body mass index (BMI) will be calculated from height and weight measurements. BMI is an estimate of body fat based on height and weight that applies to both adult men and women. Fasting blood glucose level by capillary blood from finger prick will be tested. For vital sign measurements, subjects will sit in a comfortable chair, feet uncrossed and on the floor and will be asked to rest quietly for 5 minutes before measuring blood pressure and heart rate. Arm vein will be assessed using a vein access scale test. Subject will be instructed to complete a 24-hour food recall.
Based on the results of the questionnaires, BMI calculation, health evaluation and 24-hour food recall, subjects who meet the inclusion and exclusion criteria will be invited to participate in the study. Eligible subjects will be trained and instructed to record all food and beverages consumed for a 3-day period on food record diaries. Study staff will provide the food record forms and training to the subjects.
Eligible participants will be asked to come to the center for two test days. Test Day 1 will follow the screening visit by at least a 7 day washout adhering to diet instructions.
At each Test Day visit, subjects will arrive at the clinic between 7 am and 9 am after fasting for 10 to 12 hours and in a well-hydrated and well-rested state. If they are taking medication(s) each morning, they will be asked not to take the medication(s) at home and instead to bring to the clinical nutrition center to be taken in the presence of the study investigator so the medications(s) is taken at the same time before each Study Day visit.
Study protocol adherence will be corroborated by asking about the period of fasted state. Subject will also be asked about their limitation/avoidance of polyphenolic diet the last one week and detailed food intake the 24-hour period prior to the visit to ensure consistency and compliance with the protocol requirements. Subjects experiencing unusual stressful events (such as loss of job, loss of loved one, divorce, etc…) will be rescheduled to a later time agreed upon by the subject and investigator. Subject will be asked about their medication intake and health status since their last visit to ensure that subjects are maintaining their good health and medication intake.
After confirming compliance with protocol, anthropometric measurements and vital signs (blood pressure, heart rate and ear temperature) will be taken. A finger prick for fasting blood glucose will be taken to confirm if subject is fasting. A licensed healthcare professional (LHCP) will evaluate and place a catheter on antecubital site of subject's non-dominant arm. A catheter is a thin flexible tube that allows sampling of blood through one port throughout the Study Day. Once the catheter is placed, a baseline blood sample will be taken (Time point T -5). Subject will be asked to rest for 5 minutes, and then another baseline blood sample will be taken (T 0). After completing 2 baseline blood sampling, subjects will receive a serving of 100% orange juice or 100% orange juice with orange pomace fiber based on computer generated randomization sequence. The randomization sequence will be assigned to each subject on the first Study Day visit (Test Day 1). Additional blood samples will be taken at 15, 30, 45, 60, 75, 90, 105 and 120 minutes after the start of the orange juice. Subjects are allowed to drink water after 60 min and the amount will be recorded. After completion of all study procedures and data/sample collection for the day, the catheter will be removed and subjects will be evaluated for safety and/or discomfort/symptoms before leaving the study site. They will be given a snack and written instructions in preparation for the next visit. Study day visits will be scheduled at least 3 days apart, but not more than 7 days. Test Day 2 will be exactly the same as Test Day 1 except the treatment, which will be the other of 100% orange juice or 100% orange juice with orange pomace fiber based on computer generated randomization sequence.
- Conditions
- Healthy
- Being tested
- Active, Control
- Keywords
- orange pomace fiber, glycemic response
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ActiveDietary supplement
100% orange juice with orange pomace fiber
ControlDietary supplement
100% orange juice
| Study group | Role | What they receive |
|---|---|---|
| Active Treatment | Experimental | 100% orange juice with orange pomace fiber Receives: Dietary Supplement: Active |
| Control Treatment | Placebo comparator | 100% orange juice Receives: Dietary Supplement: Control |
What is being measured
The primary outcome is the main question the study is designed to answer.
Changes in plasma glucose concentration as measured by iAUC over a 2 hour Postprandial Test day after administration of active treatment compared to control treatment
plasma glucose concentration as measured by iAUC over a 2 hour
Measured: 2 hours
Secondary outcomes (1)
Changes in plasma insulin concentration as measured by iAUC over a 2 hour Postprandial Test day after administration of active treatment compared to control treatment
plasma insulin concentration as measured by iAUC over a 2 hour
Measured: 2 hours
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Nov 2016 (estimated)
- Study start22 Nov 2016
- Primary completion14 Feb 2017
- Study completion18 Sep 2017
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HealthyStudies of the same condition, open and under way.
- More trials run by Clinical Nutrition Research Center, Illinois Institute of TechnologyThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 12 participants (actual)
Sponsor and investigators
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Britt Burton-Freeman, Ph.D, Principal investigator, Illinois Institute of Technology
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02962375
- Sponsor's protocol ID
- IRB2016-118
- Acronym
- PEP
- Status last verified
- Jan 2021
- First submitted
- 9 Nov 2016
- Last updated
- 27 Jan 2021
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 27 Jan 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Pilot Study to Assess the Effect of Orange Pomace Fiber on Glycemic Response in Healthy Adults
- ClinicalTrials.gov ID
- NCT02962375
- Acronym / sponsor ID
- PEP / IRB2016-118
- Conditions
- Healthy
- Keywords
- orange pomace fiber, glycemic response
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 12 participants (actual)
- Lead sponsor
- Clinical Nutrition Research Center, Illinois Institute of TechnologyIndustry (pharma, biotech, devices)
- Study start
- 22 Nov 2016 (actual)
- Primary completion
- 14 Feb 2017 (actual)
- Study completion
- 18 Sep 2017 (actual)
- First posted
- 11 Nov 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Primary object is to determine if 100% orange juice with enzyme-treated orange pomace fiber compared to a 100% orange juice will reduce 2 hr glycemic response as measured by glucose area under the curve.
Secondary object is to assess if 100% orange juice with enzyme-treated orange pomace fiber compared to a 100% orange juice will reduce 2 hr insulin iAUC response.
Detailed description
The study is single-center, randomized, 2-arm, and crossover design. Twelve healthy men and women aged 20-45 will be recruited for the study. Interested subjects will be asked to come to the Clinical Nutrition Research Center (CNRC) on the IIT Campus, Chicago, IL, where the study will take place for a screening visit to determine if they are eligible to participate in the study. The screening visit will take 2-2.5 hours. Prospective subjects must read, sign and date a written Institutional Review Board (IRB) approved Informed Consent Form prior to performing any study procedure.
At the on-site screening visit, subject will be asked to arrive after overnight fasting for 10-12 hours and be well-hydrated. Subject will be instructed to aim for a water intake of at least 8-10 cups for the 24 hours before the screening visit. Determine eligibility to participate includes having subjects to complete a series of questionnaires related to their health, medication use, dietary habits, and physical activity history. Anthropocentric (height, weight and waist circumference), ear temperature, and vital signs (blood pressure and heart rate) will be measured. Body mass index (BMI) will be calculated from height and weight measurements. BMI is an estimate of body fat based on height and weight that applies to both adult men and women. Fasting blood glucose level by capillary blood from finger prick will be tested. For vital sign measurements, subjects will sit in a comfortable chair, feet uncrossed and on the floor and will be asked to rest quietly for 5 minutes before measuring blood pressure and heart rate. Arm vein will be assessed using a vein access scale test. Subject will be instructed to complete a 24-hour food recall.
Based on the results of the questionnaires, BMI calculation, health evaluation and 24-hour food recall, subjects who meet the inclusion and exclusion criteria will be invited to participate in the study. Eligible subjects will be trained and instructed to record all food and beverages consumed for a 3-day period on food record diaries. Study staff will provide the food record forms and training to the subjects.
Eligible participants will be asked to come to the center for two test days. Test Day 1 will follow the screening visit by at least a 7 day washout adhering to diet instructions.
At each Test Day visit, subjects will arrive at the clinic between 7 am and 9 am after fasting for 10 to 12 hours and in a well-hydrated and well-rested state. If they are taking medication(s) each morning, they will be asked not to take the medication(s) at home and instead to bring to the clinical nutrition center to be taken in the presence of the study investigator so the medications(s) is taken at the same time before each Study Day visit.
Study protocol adherence will be corroborated by asking about the period of fasted state. Subject will also be asked about their limitation/avoidance of polyphenolic diet the last one week and detailed food intake the 24-hour period prior to the visit to ensure consistency and compliance with the protocol requirements. Subjects experiencing unusual stressful events (such as loss of job, loss of loved one, divorce, etc…) will be rescheduled to a later time agreed upon by the subject and investigator. Subject will be asked about their medication intake and health status since their last visit to ensure that subjects are maintaining their good health and medication intake.
After confirming compliance with protocol, anthropometric measurements and vital signs (blood pressure, heart rate and ear temperature) will be taken. A finger prick for fasting blood glucose will be taken to confirm if subject is fasting. A licensed healthcare professional (LHCP) will evaluate and place a catheter on antecubital site of subject's non-dominant arm. A catheter is a thin flexible tube that allows sampling of blood through one port throughout the Study Day. Once the catheter is placed, a baseline blood sample will be taken (Time point T -5). Subject will be asked to rest for 5 minutes, and then another baseline blood sample will be taken (T 0). After completing 2 baseline blood sampling, subjects will receive a serving of 100% orange juice or 100% orange juice with orange pomace fiber based on computer generated randomization sequence. The randomization sequence will be assigned to each subject on the first Study Day visit (Test Day 1). Additional blood samples will be taken at 15, 30, 45, 60, 75, 90, 105 and 120 minutes after the start of the orange juice. Subjects are allowed to drink water after 60 min and the amount will be recorded. After completion of all study procedures and data/sample collection for the day, the catheter will be removed and subjects will be evaluated for safety and/or discomfort/symptoms before leaving the study site. They will be given a snack and written instructions in preparation for the next visit. Study day visits will be scheduled at least 3 days apart, but not more than 7 days. Test Day 2 will be exactly the same as Test Day 1 except the treatment, which will be the other of 100% orange juice or 100% orange juice with orange pomace fiber based on computer generated randomization sequence.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Single blind (participant)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Active Treatment | Experimental | Dietary Supplement: Active100% orange juice with orange pomace fiber |
| Control Treatment | Placebo comparator | Dietary Supplement: Control100% orange juice |
Who may qualify
- Ages
- 20 to 45 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (7 listed)
- Subject is a male or female, 20-45 years of age, inclusive.
- Subject has a BMI of 20.0-24.9 kg/m2, inclusive and weight ≥ 110 lb. at screening visit.
- Subject is willing to maintain his/her usual physical activity pattern throughout the study period.
- Subject is willing to follow study instructions including compliance with consumption of study beverage, and study visit schedule.
- Subject is judged to be in good health on the basis of the medical history.
Key exclusion criteria (14 listed)
- Subject has fasting glucose ≥100 mg/dL.
- Subject has uncontrolled hypertension (systolic blood pressure ≥160 mm Hg or diastolic blood pressure ≥100 mm Hg) at screening visit.
- Subject has had major trauma or a surgical event within 2 months of the study.
- Subject has had a weight change ≥4.5 kg within 2 months of visit.
- Subject has a history or presence of clinically important endocrine, cardiovascular (including, but not limited to, atherosclerotic disease, history of myocardial infarction, peripheral arterial disease, stroke), pulmonary, biliary, or gastrointestinal disorders that, in the opinion of the Investigator, could interfere with the interpretation of the study results.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Active100% orange juice with orange pomace fiber | Dietary supplement | Active Treatment |
| Control100% orange juice | Dietary supplement | Control Treatment |
Primary outcome
Changes in plasma glucose concentration as measured by iAUC over a 2 hour Postprandial Test day after administration of active treatment compared to control treatment
Time frame: 2 hours
plasma glucose concentration as measured by iAUC over a 2 hour
1 secondary outcome
Changes in plasma insulin concentration as measured by iAUC over a 2 hour Postprandial Test day after administration of active treatment compared to control treatment
Time frame: 2 hours
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Jan 2021.
- Individual participant dataSharing planned: Undecided
Related trials for Healthy
Recruiting
THE EFFECTS OF GAME-BASED EXERCISE PROGRAMS
Physical Activity, Body Image
Not yet recruitingPhase 1
A Phase I Study of GLR2053 Tablets in Chinese Healthy Adult Participants
Atopic Dermatitis
Recruiting
Colon-delivered Riboflavin and Gut Microbiota Composition
Microbiome Dysbiosis, Gut Health
Not yet recruiting
Neuroergonomic Analysis of a Brain-Computer Interface Device (BCI)
Healthy Volunteers - Male and Female
RecruitingPhase 1
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
Healthy Volunteer, Atopic Dermatitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Britt Burton-Freeman, Ph.D principal investigator
Illinois Institute of Technology
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Active in people with Healthy, run by Clinical Nutrition Research Center, Illinois Institute of Technology at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 27 Jan 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Changes in plasma glucose concentration as measured by iAUC over a 2 hour Postprandial Test day after administration of active treatment compared to control treatment (time frame: 2 hours). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Jan 2021.